Skip to main content

Advertisement

Table 3 The secondary end points in the two groups

From: Qing-Yi decoction in participants with severe acute pancreatitis: a randomized controlled trial

  Test group (n = 46) Control group (n = 39) P value
Organ complications    
Heart failure, n (%) 12 (26.1) 12 (30.8) 0.633
Duration of heart failure, days median (interquartile range)§ 0 (0–1) 0 (0–2) 0.449
Respiratory failure, n (%) 28 (60.9) 20 (51.3) 0.374
Duration of respiratory failure, days median (interquartile range)§ 1 (0–3) 1 (0–3) 0.835
ARF, n (%) 5 (10.9) 3 (7.7) 0.617
Duration of ARF, days median (interquartile range)§ 0 (0–0) 0 (0–0) 0.715
Hepatic failure, n (%) 11 (23.9) 15 (38.5) 0.147
Duration of hepatic failure, days median (interquartile range)§ 0 (0–0.3) 0 (0–4) 0.069
Paralytic ileus, n (%) 44 (95.7) 34 (87.2) 0.157
Duration of paralytic ileus, days median (interquartile range)§ 4 (2–6)a 6 (4–8) 0.014
Infection, n (%) 6 (13.0)a 14 (35.9) 0.013
ICU stay, days median (interquartile range)§ 0 (0–0) 0 (0–0) 0.209
Use of respirator, n (%) 4 (8.7) 9 (23.1) 0.066
Use of respirator, days median (interquartile range)§ 0 (0–0) 0 (0–0) 0.067
  1. Chi-square test, §Wilcoxon rank sum test. a P < 0.05 vs. control group
  2. ARF acute renal failure
  3. ICU intensive care unit